STAT

DECEMBER 9, 2023

SAN DIEGO — When the first lupus patient received CAR-T therapy, researchers watched in amazement as her autoimmune disease rapidly went into remission. Then, they monitored her disease anxiously for months, wondering if it would return — especially as her immune B cells began recovering. Now, two and a half years later, the researchers reported at the annual American Society of Hematology meeting that not only is this patient still in complete remission without the use of any

Immunization 142

Immunization 142

Pharmacy Times

DECEMBER 9, 2023

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

145

145

STAT

DECEMBER 9, 2023

SAN DIEGO — News of the Food and Drug Administration’s historic approval of the first gene therapies for sickle cell disease sparked discussion, debate, and, above all, measured optimism at this year’s meeting of the American Society of Hematology. Doctors and researchers noted that the approval of both therapies, one made by Vertex Pharmaceuticals and CRISPR Therapeutics and the other by Bluebird Bio, marked a landmark shift in the treatment of sickle cell, a disease resear

Hospitals 140

Hospitals 140

Fierce Pharma

DECEMBER 9, 2023

BCMA-targeted therapies are transforming care for multiple myeloma patients. But these immunotherapies also come with various potentially dangerous side effects. | A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions.

FDA 115

FDA 115

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 9, 2023

SAN DIEGO — Researchers on Saturday presented an unusual case of a T cell lymphoma marked with a CAR, the key synthetic protein in CAR-T therapy, here at the American Society of Hematology annual meeting. It is the first published case of the rare blood cancer that’s associated with a commercial CAR-T product, the Janssen/Legend Biotech drug Carvykti, or cilta-cel in this case.

FDA 128

FDA 128

Pharmacy Times

DECEMBER 9, 2023

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

73

73

The Guardian - Pharmaceutical Industry

DECEMBER 9, 2023

Actor was prescribed controversial high-strength drug to prevent loss of muscle after complex fractures of leg, hip and pelvis sustained on stage Stephen Fry was given the controversial painkiller OxyContin to help him to move again during his recovery from a serious fall. Now walking without a stick for the first time since the accident in September, Fry has revealed he was a reluctant user of the drug.

77

77

Pharmacy Times

DECEMBER 9, 2023

The president highlights a new curative treatment option for sickle cell disease while also expanding on the changing treatment landscape for hematologic conditions.

65

65